All In Biotech

Drug Trial Radar · NCT03561701

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 425 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

425

Actual

Start

Aug 23, 2018

Primary completion

Oct 13, 2020

Study completion Aug 3, 2021

Sponsor

Lead sponsor
Mycovia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jun 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months. Several properties of oteseconazole (VT-1161) suggest that it might be a safer and more effective treatment for RVVC than other oral antifungal medicines. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of RVVC and consists of 2 parts. The first part of the study is a 2-week period for the treatment of the patient's current VVC episode with 3 150mg doses of fluconazole. The 2nd part consists of 12 weeks, when the patient will take either oteseconazole (VT-1161) 150 mg or a placebo (according to a random assignment), and then a 36-week follow-up period. In addition, at participating sites, an amendment to the study allows US patients who complete the initial 48 weeks without experiencing a confirmed RVVC episode to continue in a 48-week observational extension period designed to evaluate the continued effectiveness of oteseconazole (VT-1161). This study is identical to VMT-VT-1161-CL-011.

Conditions

  • Recurrent Vulvovaginal Candidiasis

Interventions

  • Oteseconazole (VT-1161)Drug

    Oteseconazole (VT-1161) 150mg capsule

  • PlaceboDrug

    matching placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population.Time frame: Maintenance phase (Baseline through Week 48)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • 31215

    Phoenix, Arizona

  • 31227

    Little Rock, Arkansas

  • 31217

    Los Angeles, California

  • 31240

    Hartford, Connecticut

  • 31204

    Homestead, Florida

  • 31233

    North Bay Village, Florida

  • 31255

    Wichita, Kansas

  • 31245

    Hagerstown, Maryland

  • 31223

    Winston-Salem, North Carolina

  • 31244

    Columbus, Ohio

  • 31229

    Columbus, Ohio

  • 31222

    Englewood, Ohio

  • 31218

    Jackson, Tennessee

  • 31232

    Frisco, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.